Immunome Financial Statements (IMNM)
|
|
|
|
Report date
|
|
|
12.05.2025 |
06.08.2025 |
06.11.2025 |
03.03.2026 |
12.05.2026 |
|
12.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2.93 |
4.02 |
0.000 |
0.000 |
0.000 |
|
4.02 |
|
Operating Income, bln rub |
|
|
-44.6 |
-46.5 |
-60.1 |
-72.9 |
-59.3 |
|
-238.8 |
|
EBITDA, bln rub |
? |
|
-43.9 |
-42.7 |
-56.9 |
-69.1 |
-53.1 |
|
-233.3 |
|
Net profit, bln rub |
? |
|
-41.6 |
-43.4 |
-57.5 |
-69.9 |
-53.8 |
|
-224.6 |
|
|
OCF, bln rub |
? |
|
-53.1 |
-49.4 |
-40.5 |
-48.0 |
-58.6 |
|
-196.5 |
|
CAPEX, bln rub |
? |
|
3.67 |
0.905 |
1.12 |
4.00 |
3.00 |
|
9.02 |
|
FCF, bln rub |
? |
|
-56.7 |
-50.3 |
-41.6 |
-52.0 |
-61.6 |
|
-205.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
47.6 |
49.8 |
10.9 |
72.9 |
58.6 |
|
192.2 |
|
Cost of production, bln rub |
|
|
0.000 |
0.720 |
49.2 |
0.000 |
0.753 |
|
50.7 |
|
R&D, bln rub |
|
|
36.9 |
40.5 |
49.2 |
60.8 |
46.4 |
|
196.8 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
342.7 |
296.3 |
299.4 |
683.2 |
619.8 |
|
619.8 |
|
Net Assets, bln rub |
? |
|
307.1 |
269.3 |
263.9 |
634.3 |
588.7 |
|
588.7 |
|
Debt, bln rub |
|
|
4.77 |
4.14 |
4.01 |
3.86 |
3.69 |
|
3.69 |
|
Cash, bln rub |
|
|
317.3 |
268.0 |
272.6 |
653.5 |
582.7 |
|
582.7 |
|
Net debt, bln rub |
|
|
-312.6 |
-263.9 |
-268.6 |
-649.6 |
-579.0 |
|
-579.0 |
|
|
Ordinary share price, rub |
|
|
6.73 |
9.30 |
11.7 |
21.5 |
21.9 |
|
18.7 |
|
Number of ordinary shares, mln |
|
|
79.4 |
87.0 |
88.0 |
87.4 |
113.1 |
|
113.1 |
|
|
Market cap, bln rub |
|
|
534 |
809 |
1 030 |
1 876 |
2 474 |
|
2 120 |
|
EV, bln rub |
? |
|
222 |
545 |
761 |
1 227 |
1 895 |
|
1 541 |
|
Book value, bln rub |
|
|
307 |
269 |
264 |
634 |
589 |
|
589 |
|
|
EPS, rub |
? |
|
-0.52 |
-0.50 |
-0.65 |
-0.80 |
-0.48 |
|
-1.99 |
|
FCF/share, rub |
|
|
-0.71 |
-0.58 |
-0.47 |
-0.59 |
-0.54 |
|
-1.82 |
|
BV/share, rub |
|
|
3.87 |
3.09 |
3.00 |
7.26 |
5.20 |
|
5.20 |
|
|
EBITDA margin, % |
? |
|
-1 501% |
-1 063% |
|
|
|
|
-5 810% |
|
Net margin, % |
? |
|
-1 423% |
-1 081% |
|
|
|
|
-5 594% |
|
FCF yield, % |
? |
|
-30.2% |
-23.0% |
-18.6% |
-10.7% |
-8.31% |
|
-9.69% |
|
ROE, % |
? |
|
-66.8% |
-78.9% |
-84.4% |
-33.5% |
-38.2% |
|
-38.2% |
|
ROA, % |
? |
|
-59.9% |
-71.7% |
-74.4% |
-31.1% |
-36.2% |
|
-36.2% |
|
|
P/E |
? |
|
-2.61 |
-3.81 |
-4.62 |
-8.83 |
-11.0 |
|
-9.44 |
|
P/FCF |
|
|
-3.31 |
-4.35 |
-5.36 |
-9.35 |
-12.0 |
|
-10.3 |
|
P/S |
? |
|
48.9 |
64.3 |
106.4 |
270.3 |
616.3 |
|
528.1 |
|
P/BV |
? |
|
1.74 |
3.01 |
3.90 |
2.96 |
4.20 |
|
3.60 |
|
EV/EBITDA |
? |
|
-1.27 |
-2.95 |
-3.84 |
-5.77 |
-8.55 |
|
-6.61 |
|
Debt/EBITDA |
|
|
1.78 |
1.43 |
1.35 |
3.06 |
2.61 |
|
2.48 |
|
|
R&D/CAPEX, % |
|
|
1 006% |
4 470% |
4 408% |
1 520% |
1 545% |
|
2 181% |
|
|
CAPEX/Revenue, % |
|
|
125.3% |
22.5% |
|
|
|
|
224.7% |
|
| Immunome shareholders |
